Thursday, July 18, 2019 7:07:11 AM
[url][/url][tag]https://finance.yahoo.com/news/co-diagnostics-inc-coprimers-high-103000250.html[/tag]
Salt Lake City, UT, July 18, 2019 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today favorable results of a study to detect cancer mutations using its patented CoPrimer™ technology, with applications in liquid biopsy and companion diagnostic tests.
Unlike invasive and more expensive tissue biopsies, liquid biopsies identify traces of cancer in a simple blood draw. The Company's study, performed on circulating free DNA (cfDNA) reference materials, demonstrated highly specific detection of the ten mutations associated with non-small cell lung cancer (NSCLC), reliably and successfully distinguishing the genes with mutations from those without. The CoPrimer-based polymerase chain reaction (PCR) test was also shown to be highly sensitive, identifying the NSCLC genes at the lowest possible percentage available with the reference material.
PCR-based liquid biopsy tests are simpler and more affordable compared to other methods of monitoring cancer patients, such as whole-body imaging, although relatively few blood tests are currently available. The results of the Company's study also confirm the usefulness of the CoPrimer platform as a cancer treatment companion diagnostic, to monitor treatment response and provide early detection of drug resistance mutations.
Dwight Egan, Co-Diagnostics CEO, commented: "The global cancer diagnostics market was recently valued at $144 bn and growing, as healthcare professionals focus on more effective diagnostics and monitoring to battle one of the leading causes of death worldwide. We anticipate a large and ready market among clinical laboratories for NSCLC and other cancer liquid biopsy tests designed on our CoPrimer platform. Given the relatively few PCR liquid biopsy tests on the market and the growing demand for more, we believe the advantages of our technology will create meaningful revenue opportunities and position Co-Diagnostics to become a leading innovator of liquid biopsy solutions.”
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.[url][/url][tag]insert-text-here[/tag]
Recent CODX News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:05:53 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:01:37 PM
- Co-Diagnostics, Inc. Reports First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:01:00 PM
- Co-Diagnostics, Inc. Announces First Quarter 2024 Earnings Release Date and Webcast • PR Newswire (US) • 04/25/2024 01:30:00 PM
- Co-Diagnostics, Inc. to Host Booth and Deliver Presentation at APRC 2024 in Taiwan • PR Newswire (US) • 04/24/2024 01:30:00 PM
- Co-Diagnostics, Inc. Inaugurates New Manufacturing Facility in Utah with Ribbon Cutting Event • PR Newswire (US) • 04/12/2024 01:30:00 PM
- Co-Diagnostics, Inc. Appoints New President and Other C-Level Positions • PR Newswire (US) • 04/04/2024 01:30:00 PM
- Co-Diagnostics, Inc. CEO Delivers Manufacturing and Commercialization Update in Conference Keynote Address • PR Newswire (US) • 03/21/2024 01:30:00 PM
- Co-Diagnostics, Inc. CEO to Deliver Keynote Address at MarketsandMarkets 2024 in London, England • PR Newswire (US) • 03/18/2024 01:30:00 PM
- Co-Diagnostics, Inc. Reports Full Year 2023 Financial Results • PR Newswire (US) • 03/14/2024 08:01:00 PM
- Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test • PR Newswire (US) • 03/07/2024 02:30:00 PM
- Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2023 Earnings Release Date and Webcast • PR Newswire (US) • 02/29/2024 02:30:00 PM
- Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for February 2024 • PR Newswire (US) • 02/01/2024 02:30:00 PM
- Co-Diagnostics, Inc. to Host Booth at CES 2024 January 9-12 • PR Newswire (US) • 01/03/2024 02:30:00 PM
- Co-Diagnostics, Inc. Completes Submission to FDA for Co-Dx PCR Pro • PR Newswire (US) • 12/27/2023 02:30:00 PM
- Co-Diagnostics, Inc. to Participate in the Piper Sandler 35th Annual Healthcare Conference in New York City on November 30, 2023 • PR Newswire (US) • 11/29/2023 02:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:50:41 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:38:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/27/2023 09:37:56 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:05:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:01:35 PM
- Co-Diagnostics, Inc. Reports Third Quarter 2023 Financial Results • PR Newswire (US) • 11/09/2023 09:01:00 PM
- Co-Diagnostics, Inc. Announces Additional Grant Award for Tuberculosis Test in Development • PR Newswire (US) • 11/02/2023 01:30:00 PM
- Co-Diagnostics, Inc. Shares List of Upcoming Industry Conferences and Events for November 2023 • PR Newswire (US) • 10/31/2023 01:30:00 PM
- Co-Diagnostics, Inc. Announces Third Quarter 2023 Earnings Release Date and Webcast • PR Newswire (US) • 10/26/2023 01:30:00 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM